Melanotan II

Melanotan II (MT-II) is a synthetic cyclic heptapeptide analog of alpha-melanocyte stimulating hormone (alpha-MSH) with the full chemical sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2 and a molecular weight of approximately 1024 Da. It was originally designed and synthesized in the 1980s at the University of Arizona by Dr. Victor Hruby and colleagues in the Department of Chemistry, as part of a program to develop potent, metabolically stable melanocortin receptor agonists. The key structural modifications that distinguish MT-II from native alpha-MSH include N-terminal acetylation, replacement of methionine with norleucine (Nle) to prevent oxidation, substitution of D-phenylalanine for L-phenylalanine to increase receptor binding affinity, and lactam cyclization between the Asp and Lys side chains to constrain the peptide backbone into its bioactive conformation. These changes give MT-II roughly 1,000-fold greater potency than linear alpha-MSH and dramatically improved resistance to enzymatic degradation.

The primary mechanism of action of Melanotan II is activation of the melanocortin 1 receptor (MC1R) on epidermal melanocytes. When MT-II binds MC1R, it triggers a Gs-protein-coupled signaling cascade that increases intracellular cyclic AMP (cAMP), which in turn activates protein kinase A (PKA) and the transcription factor CREB. CREB then upregulates MITF (microphthalmia-associated transcription factor), the master regulator of melanogenesis. MITF drives expression of tyrosinase, TRP-1, and TRP-2, the enzymes that convert L-tyrosine through L-DOPA to eumelanin. The result is increased melanin synthesis and transfer of melanosomes to surrounding keratinocytes, producing visible skin darkening.

The clinical research on Melanotan II began with Phase I trials at the University of Arizona College of Medicine. In the key study by Dorr et al. (1996), subcutaneous administration of MT-II at doses of 0.010-0.025 mg/kg produced statistically significant skin darkening as measured by spectrophotometric reflectance. Subjects showed measurable increases in melanin density within 5 days of initiating treatment, with peak darkening observed at 2-3 weeks. Skin biopsy analysis confirmed that the darkening was due to genuine eumelanin upregulation, not simply melanin redistribution. Importantly, eumelanin (the brown-black pigment) rather than pheomelanin (the red-yellow pigment) was preferentially stimulated, and eumelanin is the form that provides actual UV photoprotection. Studies have shown MC1R activation and the resulting eumelanin production reduce UV-induced DNA damage (cyclobutane pyrimidine dimers) by 30-50%.

Melanotan II is a non-selective melanocortin agonist, meaning it also activates MC3R, MC4R, and MC5R in addition to MC1R. MC4R activation in the hypothalamus produces appetite-suppressing effects and has been linked to increased sexual arousal, the latter observation being what led to the development of PT-141 (bremelanotide) as a dedicated sexual health compound. MC3R activation plays a role in energy homeostasis and fat metabolism. These multi-receptor effects mean that users of MT-II may experience appetite reduction and increased libido in addition to tanning.

The pharmacokinetics of subcutaneous MT-II show rapid absorption with a time to peak plasma concentration (Tmax) of approximately 30-60 minutes. The elimination half-life is estimated at 1.5-2 hours, though the downstream biological effects on melanogenesis persist much longer because melanin synthesis, once activated, continues for days after receptor stimulation. This is why maintenance dosing can be spaced further apart than the half-life would suggest. Bioavailability following subcutaneous injection is high, estimated at >90%. The peptide is primarily cleared by renal filtration and enzymatic degradation.

For reconstitution and storage, lyophilized MT-II should be stored at -20 degrees C before reconstitution. Reconstitute with bacteriostatic water (0.9% benzyl alcohol) to the desired concentration. Once reconstituted, store at 2-8 degrees C (refrigerated) and use within 4-6 weeks. Avoid repeated freeze-thaw cycles. The lyophilized powder is stable for 24+ months at -20 degrees C. Protect from light, as the tryptophan residue is photosensitive.

The most commonly reported side effects in clinical trials included transient facial flushing (occurring in approximately 80% of subjects at higher doses), mild nausea (usually only with initial doses and resolving with continued use), and appetite suppression. Nausea was dose-dependent and could be mitigated by starting at lower doses (0.25-0.5 mg) and titrating upward. Dorr et al. reported no serious adverse events and no clinically significant changes in laboratory values, vital signs, or ECG parameters. Pre-existing nevi (moles) should be monitored, as increased melanocyte activity can darken existing pigmented lesions. A baseline dermatological assessment is recommended before use.